[THE INVESTOR] On Sept. 13 Whanin Pharm (016580) slightly edged down 0.63% to 15,650 won (US$13.98). It had declined 6.87% through the past month. Standard deviation, the risk index for stock price, was 1.9% on the same period of time over one month.
Compared with its close competitors within the same industry, KOSPI, even though the monthly earnings rate of Whanin Pharm was negative, its volatility for one month was lower than that of its peer group. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -3.6%. With low volatility, the return-on-risk remained around the average of its peer group. In spite of that, the return-on-risk is much better than the industrial mean, -3.8, and thus the industrial comparison performance was positive.
While institutions have been buying Whanin Pharm during the past two trading days, foreigners have been selling during the past two trading days. As a shareholding sum by investor group for the past four weeks, institutions have bought 119,790 shares with trending trade. However, during the same period, foreigners have sold 4,348 shares and individuals have sold 115,442 shares with a decreasing position.
Cumulated shareholdings per investor group (1Mo) Total shareholdings per investor group
By HeRo (hero@heraldcorp.com)
This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.
MOST POPULAR